Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, Hemnes AR, Kawut SM, Kline JA, Kolb TM, Mathai SC, Mercier O, Michelakis ED, Naeije R, Tuder RM, Ventetuolo CE, Vieillard-Baron A, Voelkel NF, Vonk-Noordegraaf A, Hassoun PM; American Thoracic Society Assembly on Pulmonary Circulation.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):e15-e43. doi: 10.1164/rccm.201806-1160ST.

PMID:
30109950
2.

Immunity Comes to Play in the "Sex Paradox" of Pulmonary Arterial Hypertension.

Osman MS, Michelakis ED.

Circ Res. 2018 Jun 8;122(12):1635-1637. doi: 10.1161/CIRCRESAHA.118.313075. No abstract available.

PMID:
29880496
3.

Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.

Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Paulin R, Provencher S, Bonnet S.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):90-103. doi: 10.1164/rccm.201708-1751OC.

PMID:
29394093
4.

PVDOMICS Drive the Pulmonary Hypertension Field Into the Precision Medicine Era.

Michelakis ED.

Circ Res. 2017 Oct 27;121(10):1106-1108. doi: 10.1161/CIRCRESAHA.117.312022. No abstract available.

PMID:
29074523
5.

Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.

Michelakis ED, Gurtu V, Webster L, Barnes G, Watson G, Howard L, Cupitt J, Paterson I, Thompson RB, Chow K, O'Regan DP, Zhao L, Wharton J, Kiely DG, Kinnaird A, Boukouris AE, White C, Nagendran J, Freed DH, Wort SJ, Gibbs JSR, Wilkins MR.

Sci Transl Med. 2017 Oct 25;9(413). pii: eaao4583. doi: 10.1126/scitranslmed.aao4583.

6.

Oxygen Sensing in the Pulmonary Circulation: A Fluid State of Affairs.

Sutendra G, Michelakis ED.

Circ Res. 2017 Aug 4;121(4):323-325. doi: 10.1161/CIRCRESAHA.117.311518. No abstract available.

PMID:
28775008
7.

An Official American Thoracic Society Workshop Report: Obesity and Metabolism. An Emerging Frontier in Lung Health and Disease.

Suratt BT, Ubags NDJ, Rastogi D, Tantisira KG, Marsland BJ, Petrache I, Allen JB, Bates JHT, Holguin F, McCormack MC, Michelakis ED, Black SM, Jain M, Mora AL, Natarajan V, Miller YI, Fessler MB, Birukov KG, Summer RS, Shore SA, Dixon AE; Allergy, Immunology, and Inflammation Assembly.

Ann Am Thorac Soc. 2017 Jun;14(6):1050-1059. doi: 10.1513/AnnalsATS.201703-263WS.

8.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

9.

A Paradigm Shift Is Needed in the Field of Pulmonary Arterial Hypertension for Its Entrance Into the Precision Medicine Era.

Gurtu V, Michelakis ED.

Circ Res. 2016 Dec 9;119(12):1276-1279. Review. No abstract available.

PMID:
27932471
10.

Metabolic control of epigenetics in cancer.

Kinnaird A, Zhao S, Wellen KE, Michelakis ED.

Nat Rev Cancer. 2016 Nov;16(11):694-707. doi: 10.1038/nrc.2016.82. Epub 2016 Sep 16. Review.

PMID:
27634449
11.

Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription.

Boukouris AE, Zervopoulos SD, Michelakis ED.

Trends Biochem Sci. 2016 Aug;41(8):712-730. doi: 10.1016/j.tibs.2016.05.013. Epub 2016 Jun 23. Review.

PMID:
27345518
12.

Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.

Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, Zervopoulos S, Stenson T, Sutendra G, Pink DB, Carmine-Simmen K, Moore R, Lewis JD, Michelakis ED.

Eur Urol. 2016 Apr;69(4):734-744. doi: 10.1016/j.eururo.2015.09.014. Epub 2016 Feb 18.

PMID:
26433571
13.

2-Methoxyestradiol: A Hormonal Metabolite Modulates Stimulated T-Cells Function and proliferation.

Luc JG, Paulin R, Zhao JY, Freed DH, Michelakis ED, Nagendran J.

Transplant Proc. 2015 Jul-Aug;47(6):2057-66. doi: 10.1016/j.transproceed.2015.05.021.

PMID:
26293097
14.

Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension.

Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S.

Circulation. 2015 Sep 8;132(10):932-43. doi: 10.1161/CIRCULATIONAHA.115.016382. Epub 2015 Jul 10.

PMID:
26162916
15.

Addressing Complexity in Pulmonary Hypertension: The FoxO1 Case.

Paulin R, Michelakis ED.

Circ Res. 2015 May 22;116(11):1732-5. doi: 10.1161/CIRCRESAHA.115.305773. No abstract available.

PMID:
25999418
16.

Emerging therapies and future directions in pulmonary arterial hypertension.

Gurtu V, Michelakis ED.

Can J Cardiol. 2015 Apr;31(4):489-501. doi: 10.1016/j.cjca.2015.01.028. Epub 2015 Jan 28. Review.

PMID:
25840098
17.

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.

Chu QS, Sangha R, Spratlin J, Vos LJ, Mackey JR, McEwan AJ, Venner P, Michelakis ED.

Invest New Drugs. 2015 Jun;33(3):603-10. doi: 10.1007/s10637-015-0221-y. Epub 2015 Mar 13.

PMID:
25762000
18.

Metabolic modulation of cancer: a new frontier with great translational potential.

Kinnaird A, Michelakis ED.

J Mol Med (Berl). 2015 Feb;93(2):127-42. doi: 10.1007/s00109-014-1250-2. Epub 2015 Jan 14. Review.

PMID:
25586106
19.

A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension.

Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S, Michelakis ED.

Circ Res. 2015 Jan 2;116(1):56-69. doi: 10.1161/CIRCRESAHA.115.303910. Epub 2014 Oct 6.

PMID:
25287062
20.

Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans.

Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, Haromy A, Webster L, Provencher S, Bonnet S, Michelakis ED.

Cell Metab. 2014 Nov 4;20(5):827-839. doi: 10.1016/j.cmet.2014.08.011. Epub 2014 Oct 2.

21.

A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation.

Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, Hashimoto K, Zhang N, Flaim E, Michelakis ED.

Cell. 2014 Jul 3;158(1):84-97. doi: 10.1016/j.cell.2014.04.046.

22.

Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling.

Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, Sack MN, Lehner R, Gupta MP, Michelakis ED, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD.

Cardiovasc Res. 2014 Sep 1;103(4):485-97. doi: 10.1093/cvr/cvu156. Epub 2014 Jun 25.

23.

The metabolic theory of pulmonary arterial hypertension.

Paulin R, Michelakis ED.

Circ Res. 2014 Jun 20;115(1):148-64. doi: 10.1161/CIRCRESAHA.115.301130. Review.

PMID:
24951764
24.

Pulmonary arterial hypertension: yesterday, today, tomorrow.

Michelakis ED.

Circ Res. 2014 Jun 20;115(1):109-14. doi: 10.1161/CIRCRESAHA.115.301132. No abstract available.

PMID:
24951761
25.

Response to Lazarus.

Michelakis ED.

Circ Res. 2014 Mar 14;114(6):e31. doi: 10.1161/CIRCRESAHA.114.303719. No abstract available.

PMID:
24625731
26.

Exogenous hydrogen sulfide (H2S) protects alveolar growth in experimental O2-induced neonatal lung injury.

Vadivel A, Alphonse RS, Ionescu L, Machado DS, O'Reilly M, Eaton F, Haromy A, Michelakis ED, Thébaud B.

PLoS One. 2014 Mar 6;9(3):e90965. doi: 10.1371/journal.pone.0090965. eCollection 2014.

27.

The metabolic basis of pulmonary arterial hypertension.

Sutendra G, Michelakis ED.

Cell Metab. 2014 Apr 1;19(4):558-73. doi: 10.1016/j.cmet.2014.01.004. Epub 2014 Feb 6. Review.

28.

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.

Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ.

J Cancer Res Clin Oncol. 2014 Mar;140(3):443-52. doi: 10.1007/s00432-014-1583-9. Epub 2014 Jan 18.

29.

Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells.

Dromparis P, Sutendra G, Paulin R, Proctor S, Michelakis ED, McMurtry MS.

J Mol Med (Berl). 2014 May;92(5):497-507. doi: 10.1007/s00109-013-1115-0. Epub 2014 Jan 10.

30.

Role for DNA damage signaling in pulmonary arterial hypertension.

Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S.

Circulation. 2014 Feb 18;129(7):786-97. doi: 10.1161/CIRCULATIONAHA.113.006167. Epub 2013 Nov 22.

PMID:
24270264
31.

Pulmonary arterial hypertension: challenges in translational research and a vision for change.

Sutendra G, Michelakis ED.

Sci Transl Med. 2013 Oct 23;5(208):208sr5. doi: 10.1126/scitranslmed.3005428. Review.

PMID:
24154604
32.

A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension.

Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED.

J Mol Med (Berl). 2013 Nov;91(11):1315-27. doi: 10.1007/s00109-013-1059-4. Epub 2013 Jul 12.

PMID:
23846254
33.

Targeting cell motility in pulmonary arterial hypertension.

Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S.

Eur Respir J. 2014 Feb;43(2):531-44. doi: 10.1183/09031936.00181312. Epub 2013 Jul 11.

34.

Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension.

Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED.

Circ Res. 2013 Jul 5;113(2):126-36. doi: 10.1161/CIRCRESAHA.112.300699. Epub 2013 May 7.

PMID:
23652801
35.

Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology.

Sutendra G, Michelakis ED.

Front Oncol. 2013 Mar 7;3:38. doi: 10.3389/fonc.2013.00038. eCollection 2013.

36.

Endothelin axis is upregulated in human and rat right ventricular hypertrophy.

Nagendran J, Sutendra G, Paterson I, Champion HC, Webster L, Chiu B, Haromy A, Rebeyka IM, Ross DB, Michelakis ED.

Circ Res. 2013 Jan 18;112(2):347-54. doi: 10.1161/CIRCRESAHA.111.300448. Epub 2012 Dec 10. Erratum in: Circ Res. 2014 Mar 14;114(6):e32.

PMID:
23233754
37.

Mitochondria in vascular health and disease.

Dromparis P, Michelakis ED.

Annu Rev Physiol. 2013;75:95-126. doi: 10.1146/annurev-physiol-030212-183804. Epub 2012 Nov 16. Review.

PMID:
23157555
38.

Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension.

Dromparis P, Paulin R, Stenson TH, Haromy A, Sutendra G, Michelakis ED.

Circulation. 2013 Jan 1;127(1):115-25. doi: 10.1161/CIRCULATIONAHA.112.133413. Epub 2012 Nov 13.

PMID:
23149668
39.

F2-isoprostanes: an emerging pulmonary arterial hypertension biomarker and potential link to the metabolic theory of pulmonary arterial hypertension?

Dromparis P, Michelakis ED.

Chest. 2012 Oct;142(4):816-820. doi: 10.1378/chest.12-0848. No abstract available.

PMID:
23032445
40.

The estrogen puzzle in pulmonary arterial hypertension.

Paulin R, Michelakis ED.

Circulation. 2012 Aug 28;126(9):1016-9. doi: 10.1161/CIRCULATIONAHA.112.126474. Epub 2012 Aug 2. No abstract available.

PMID:
22859685
41.

Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.

Ghio S, Bonderman D, Felix SB, Ghofrani HA, Michelakis ED, Mitrovic V, Oudiz RJ, Frey R, Roessig L, Semigran MJ.

Eur J Heart Fail. 2012 Aug;14(8):946-53. doi: 10.1093/eurjhf/hfs071. Epub 2012 Jun 20.

42.

Human internal mammary artery (IMA) transplantation and stenting: a human model to study the development of in-stent restenosis.

Hua X, Deuse T, Michelakis ED, Haromy A, Tsao PS, Maegdefessel L, Erben RG, Bergow C, Behnisch BB, Reichenspurner H, Robbins RC, Schrepfer S.

J Vis Exp. 2012 May 9;(63):e3663. doi: 10.3791/3663.

43.

Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer.

Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, Parker JM, McMurtry MS, Michelakis ED.

Oncogene. 2013 Mar 28;32(13):1638-50. doi: 10.1038/onc.2012.198. Epub 2012 May 21.

PMID:
22614004
44.

Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.

Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry MS, Bleackley RC, Michelakis ED.

J Mol Med (Berl). 2011 Aug;89(8):771-83. doi: 10.1007/s00109-011-0762-2. Epub 2011 Aug 2.

PMID:
21809123
45.

The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension.

Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, Michelakis ED.

Sci Transl Med. 2011 Jun 22;3(88):88ra55. doi: 10.1126/scitranslmed.3002194.

46.

The role of Doppler echocardiography in pulmonary artery hypertension: the importance of proving the obvious.

Paterson I, Michelakis ED.

Chest. 2011 May;139(5):973-975. doi: 10.1378/chest.10-2837. No abstract available.

PMID:
21540210
47.

The role of mitochondria in pulmonary vascular remodeling.

Dromparis P, Sutendra G, Michelakis ED.

J Mol Med (Berl). 2010 Oct;88(10):1003-10. doi: 10.1007/s00109-010-0670-x. Epub 2010 Aug 24. Review.

PMID:
20734021
48.

Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension.

Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED.

Sci Transl Med. 2010 Aug 11;2(44):44ra58. doi: 10.1126/scitranslmed.3001327.

49.

A global pulmonary arterial hypertension registry: is it needed? Is it feasible? Pulmonary vascular disease: the global perspective.

Gomberg-Maitland M, Michelakis ED.

Chest. 2010 Jun;137(6 Suppl):95S-101S. doi: 10.1378/chest.09-3008.

PMID:
20522585
50.

Metabolic modulation of glioblastoma with dichloroacetate.

Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC.

Sci Transl Med. 2010 May 12;2(31):31ra34. doi: 10.1126/scitranslmed.3000677.

Supplemental Content

Loading ...
Support Center